dipyridamole1

dipyridamole

CLINICAL USE

Antiplatelet agent

DOSE IN NORMAL RENAL FUNCTION

100–200 mg 3 times dailyModified release: 200 mg twice daily

PHARMACOKINETICS

Molecular weight :504.6

%Protein binding :97–99

%Excreted unchanged in urine : 1–5

Volume of distribution (L/kg) :1.33–3.53

half-life – normal/ESRD (hrs) :9–12/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAnti-arrhythmics: effects of adenosine enhanced and extendedAnticoagulants: anticoagulant effect of coumarins, phenindione and heparin enhanced

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–.

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home